1
|
Guo F, Li Y, Yang D, Jiang X, Ren J, Miao Y, Ding F, Yu Z. Comparative pharmacokinetics of meloxicam oil suspension in pigs at different dosages following intramuscular administration. Res Vet Sci 2021; 139:172-176. [PMID: 34333251 DOI: 10.1016/j.rvsc.2021.07.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2020] [Revised: 06/27/2021] [Accepted: 07/14/2021] [Indexed: 11/24/2022]
Abstract
This study aimed to evaluate the preliminary safety of self-developed meloxicam (MEL) oil suspension and determine the comparative pharmacokinetics of it at 0.8 and 2mg/kg body weight (b.w.) dosages in pigs following a single intramuscular administration. Six rabbits were used for the study of preliminary safety and six healthy pigs were used for pharmacokinetics study by a crossover design in two periods. The muscle irritation results showed that both of the MEL oil suspension and the conventional injection had no significant changes at the dosage of 0.4 mg/kg b.w.. However, at the dosage of 2 mg/kg b.w., both of the self-developed MEL oil suspension and the MEL conventional injection showed mild irritation to muscle. Plasma concentrations of MEL were measured by ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). The MEL plasma concentrations were quantified up to 30 h and 72 h after intramuscular administration at the low- and high-dosage, respectively. The difference was statistically significant (P < 0.05) between different dosages in pharmacokinetic parameters of t1/2λz, Cmax, AUC0-t, AUC0-μ, MRT, and Vd. The Cmax values of MEL were 1.92 ± 0.34 μg/ml and 3.03 ± 1.25 μg/ml at dosages of 0.8 and 2 mg/kg b.w. while the tmax values were 3.25 ± 1.04 h and 4.00 ± 1.26 h, respectively. The pharmacokinetics results of self-developed MEL oil suspension demonstrated that the retention time of it in pigs was prolonged, showing the sustained-release effect. Therefore, Oil suspension was an ideal new drug loading form of MEL.
Collapse
Affiliation(s)
- Fanxi Guo
- Laboratory of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China.
| | - Ying Li
- Laboratory of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China.
| | - Dawei Yang
- China Institute of Veterinary Drug Control, Beijing 100081, China
| | - Xiangyuan Jiang
- Laboratory of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China.
| | - Juncai Ren
- Laboratory of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China.
| | - Yingxue Miao
- Laboratory of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China
| | - Fangyi Ding
- Laboratory of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China
| | - Zugong Yu
- Laboratory of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China.
| |
Collapse
|
2
|
Park JS, Kim S, Lee J, Choi JC, Kim Y, Park CW, Lee S. Preliminary bioequivalence of an oral integrating film formulation containing meloxicam with a suspension formulation in beagle dogs. J Vet Pharmacol Ther 2020; 44:342-348. [PMID: 33295645 DOI: 10.1111/jvp.12940] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Accepted: 11/25/2020] [Indexed: 11/28/2022]
Abstract
The oral disintegrating film (ODF) has advantages over suspension and tablet. These include convenience of administration, patient compliance, and accurate dosing. We evaluated the bioequivalence between the ODF and the meloxicam suspension by using a crossover design with a 3-week washout period. Six healthy male beagle dogs were randomized to receive both formulations of meloxicam, 2 mg. Plasma meloxicam concentrations were measured at the same times. From the start until maximum concentration, the initial absorption of the ODF meloxicam formulation was more rapid (2.08 ± 1.56 hr) as compared to the suspension (3.33 ± 1.03 hr). Mean elimination half-lives were 28.77 ± 4.01 and 32.85 ± 9.79 hr for the ODF and the suspension, respectively. Bioequivalence of the ODF was confirmed, based on the relative ratios of geometric mean concentrations (and 90% confidence intervals within the range of 80%-125%) for a maximum concentration of 101.05% (88.59-115.25), for the area under the plasma concentration-time curve (AUC) to the last sampling time of 96.07% (87.06-115.25), and for AUC to infinity of 92.65% (86.76-98.94). The meloxicam ODF may be used as an alternative to suspension formulations in the treatment of inflammatory joint diseases and painful musculoskeletal disorders.
Collapse
Affiliation(s)
- Jong-Shik Park
- Medical Device Development Center, Osong Medical Innovation Foundation, Cheongju-si, Korea.,College of Veterinary Medicine, Chungbuk National University, Cheongju-si, Korea
| | - Sungmin Kim
- New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Korea.,College of Pharmacy, Chungbuk National University, Cheongju-si, Korea
| | - Jaeyeon Lee
- New Drug Development Center, Osong Medical Innovation Foundation, Cheongju-si, Korea.,College of Pharmacy, Chungnam National University, Daejeon, Korea
| | - Jae-Cheol Choi
- College of Pharmacy, Chungbuk National University, Cheongju-si, Korea
| | - YoungAh Kim
- Korea Bioprocessing Training Center, Osong Medical Innovation Foundation, Cheongju-si, Korea
| | - Chun-Woong Park
- College of Pharmacy, Chungbuk National University, Cheongju-si, Korea
| | - Soohan Lee
- Laboratory Animal Center, Osong Medical Innovation Foundation, Cheongju-si, Korea
| |
Collapse
|
3
|
Nejamkin P, Cavilla V, Clausse M, Landivar F, Lorenzutti AM, Martínez S, Del Sole MJ, Martín-Flores M. Sedative and physiologic effects of tiletamine-zolazepam following buccal administration in cats. J Feline Med Surg 2020; 22:108-113. [PMID: 30744474 PMCID: PMC10814565 DOI: 10.1177/1098612x19827116] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2024]
Abstract
OBJECTIVES The aim of this study was to describe the sedative and some physiological effects of tiletamine-zolazepam following buccal administration (BA) in cats. METHODS Seven healthy spayed European shorthair cats (three males, four females) were studied twice in this randomized, blinded, crossover study. Each cat received two doses of tiletamine-zolazepam by BA: the low-dose (LD) group consisted of 5 mg/kg of each drug, and the high-dose (HD) group consisted of 7.5 mg/kg of each. Baseline systolic blood pressure (SAP), heart rate (HR), respiratory rate (RR) and a sedation score were recorded prior to administration of each treatment. The same variables plus the percentage of hemoglobin saturated with oxygen as measured by pulse oximetry (SpO2) were recorded at predefined intervals for the next 2 h. RESULTS All cats completed the study. No retching or vomiting were observed. Hypersalivation was observed in 0/7 and 3/7 for LD and HD groups, respectively (P = 0.2). There were significant changes in scores over time for posture, response to clippers and response to manual restraint for both groups, without differences between groups. RR, HR and SAP changed significantly over time. SAP and RR were significantly lower for the HD than for the LD group. No values for hemoglobin saturation <95% were observed. CONCLUSIONS AND RELEVANCE BA of tiletamine-zolazepam at the doses studied here is a simple and effective method for chemical restraint in cats, where the LD group had a lower impact on SAP and RR than the HD group.
Collapse
Affiliation(s)
- Pablo Nejamkin
- Hospital for Small Animals, Faculty of Veterinary Sciences, National Central University of the Province of Buenos Aires, University Campus, Tandil, Argentina
- Hospital for Large Animals, Faculty of Veterinary Sciences, National Central University of the Province of Buenos Aires, University Campus, Tandil, Argentina
| | - Verónica Cavilla
- Small Animal Medicine and Surgery, Clinical Department, Faculty of Veterinary Sciences, National Central University of the Province of Buenos Aires, University Campus, Tandil, Argentina
| | - María Clausse
- General Clinical Surgery Department, Faculty of Veterinary Sciences, National Central University of the Province of Buenos Aires, University Campus, Tandil, Argentina
- Veterinary Research Center of Tandil (CIVETAN, CONICET-CICPBA), Faculty of Veterinary Sciences, National Central University of the Province of Buenos Aires, University Campus, Tandil, Argentina
| | - Florencia Landivar
- Hospital for Large Animals, Faculty of Veterinary Sciences, National Central University of the Province of Buenos Aires, University Campus, Tandil, Argentina
| | - Augusto M Lorenzutti
- Pharmacology and Toxicology, Faculty of Agricultural Sciences, Catholic University of Córdoba, Córdoba, Argentina
| | - Sofía Martínez
- Small Animal Medicine and Surgery, Clinical Department, Faculty of Veterinary Sciences, National Central University of the Province of Buenos Aires, University Campus, Tandil, Argentina
| | - María J Del Sole
- Hospital for Large Animals, Faculty of Veterinary Sciences, National Central University of the Province of Buenos Aires, University Campus, Tandil, Argentina
- Veterinary Research Center of Tandil (CIVETAN, CONICET-CICPBA), Faculty of Veterinary Sciences, National Central University of the Province of Buenos Aires, University Campus, Tandil, Argentina
| | - Manuel Martín-Flores
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
| |
Collapse
|
4
|
Rajeswari SR, Gowda TM, Kumar TAB, Thimmasetty J, Mehta DS. An appraisal of innovative meloxicam mucoadhesive films for periodontal postsurgical pain control: A double-blinded, randomized clinical trial of effectiveness. Contemp Clin Dent 2015; 6:299-304. [PMID: 26321824 PMCID: PMC4549976 DOI: 10.4103/0976-237x.161857] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Background and Objective: Transmucosal analgesic delivery is a promising approach to periodontal postoperative pain management. The purpose of this clinical trial is to appraise the effectiveness of transmucosal drug delivery system with meloxicam films and to identify its minimum effective dosage via this route after periodontal flap surgery. Materials and Methods: The analgesic mucoadhesive films were formulated using meloxicam and hydroxypropyl methyl cellulose polymer by solvent casting method. The sample size consisted of 60 chronic periodontitis patients who require periodontal flap surgery. The subjects were randomized using lottery method into four groups (Group A - 45 mg; B - 30 mg; C - 20 mg; D - 10 mg meloxicam per film). After periodontal flap surgery, the respective meloxicam mucoadhesive films were placed over the surgical site and were removed on 4th day of postsurgery. The primary outcome measure was postsurgical pain level and recorded at 1st, 2nd, 3rd, 4th, 5th, 24th, and 48th h using a 0–10 mm visual analog scale with markings from 0 = no pain to 10 = extreme pain. Results: The postoperative pain control observed in Groups A and B was found to be effective, and the patient comfort level was very satisfactory. Whereas in Group C, it was found to be high in the first 3 h postsurgically, after which adequate pain relief was seen. Group D exhibited inadequate pain relief. No adverse reactions were noted after applying the film in any of the groups. Conclusion: Transmucosal delivery of meloxicam was found to be effective and safe in postsurgical pain control of periodontal flap surgery. The minimum effective dosage via this route for meloxicam was found to be with 30 mg mucoadhesive films.
Collapse
Affiliation(s)
- S Raja Rajeswari
- Department of Periodontics, Bapuji Dental College and Hospital, Davangere, Karnataka, India
| | - Triveni M Gowda
- Department of Periodontics, Bapuji Dental College and Hospital, Davangere, Karnataka, India
| | - Tarun A B Kumar
- Department of Periodontics, Bapuji Dental College and Hospital, Davangere, Karnataka, India
| | - J Thimmasetty
- Department of Pharmaceutics, Bapuji Pharmacy College, Davangere, Karnataka, India
| | - Dhoom Singh Mehta
- Department of Periodontics, Bapuji Dental College and Hospital, Davangere, Karnataka, India
| |
Collapse
|
5
|
Pairis-Garcia MD, Johnson AK, KuKanich B, Wulf L, Millman ST, Stalder KJ, Karriker LA, Coetzee JF. Pharmacokinetics of meloxicam in mature swine after intravenous and oral administration. J Vet Pharmacol Ther 2014; 38:265-70. [DOI: 10.1111/jvp.12170] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2014] [Accepted: 08/22/2014] [Indexed: 11/30/2022]
Affiliation(s)
| | - A. K. Johnson
- Department of Animal Science; Iowa State University; Ames IA USA
| | - B. KuKanich
- Department of Anatomy and Physiology; College of Veterinary Medicine; Kansas State University; Manhattan KS USA
| | - L. Wulf
- Pharmacology Analytical Support Team (PhAST); College of Veterinary Medicine; Iowa State University; Ames IA USA
| | - S. T. Millman
- Veterinary Diagnostic and Production Animal Medicine; Iowa State University; Ames IA USA
| | - K. J. Stalder
- Department of Animal Science; Iowa State University; Ames IA USA
| | - L. A. Karriker
- Swine Medicine Education Center; College of Veterinary Medicine; Iowa State University; Ames IA USA
| | - J. F. Coetzee
- Pharmacology Analytical Support Team (PhAST); College of Veterinary Medicine; Iowa State University; Ames IA USA
- Veterinary Diagnostic and Production Animal Medicine; Iowa State University; Ames IA USA
| |
Collapse
|
6
|
Liew KB, Loh GOK, Tan YTF, Peh KK. Improved protein deproteinization method for the determination of meloxicam in human plasma and application in pharmacokinetic study. Biomed Chromatogr 2014; 28:1782-8. [DOI: 10.1002/bmc.3221] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2013] [Revised: 02/11/2014] [Accepted: 03/28/2014] [Indexed: 11/07/2022]
Affiliation(s)
- Kai Bin Liew
- School of Pharmaceutical Sciences; Universiti Sains Malaysia; 11800 Minden Penang Malaysia
| | - Gabriel Onn Kit Loh
- School of Pharmaceutical Sciences; Universiti Sains Malaysia; 11800 Minden Penang Malaysia
| | - Yvonne Tze Fung Tan
- School of Pharmaceutical Sciences; Universiti Sains Malaysia; 11800 Minden Penang Malaysia
| | - Kok Khiang Peh
- School of Pharmaceutical Sciences; Universiti Sains Malaysia; 11800 Minden Penang Malaysia
| |
Collapse
|
7
|
Cozzi EM, Spensley MS. Multicenter randomized prospective clinical evaluation of meloxicam administered via transmucosal oral spray in client-owned dogs. J Vet Pharmacol Ther 2013; 36:609-16. [PMID: 23550740 DOI: 10.1111/jvp.12050] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2012] [Accepted: 02/25/2013] [Indexed: 11/27/2022]
Abstract
The clinical safety and efficacy of a transmucosal oral spray (TMOS) formulation of meloxicam was evaluated for the control of pain and inflammation associated with osteoarthritis in dogs. A total of 280 client-owned dogs were enrolled at fourteen veterinary clinics: there were 187 dogs in the meloxicam TMOS group and 93 in the placebo control group. Dogs received placebo or treatment spray once daily for twenty-eight days. Improvement in signs of osteoarthritis was measured using client-specific outcome measures (CSOM) made at days 14 and 28 and veterinary assessments of lameness and pain on palpation made at day 28. A significantly higher number of dogs in the meloxicam TMOS group were treatment successes at 28 days (72.6%) compared with the placebo group (46.9%), based on CSOM scores. Total CSOM scores were significantly lower in the meloxicam TMOS-treated group compared with the placebo group at both 14 and 28 days. Differences between treatment groups were not observed in veterinary assessments. Gastrointestinal effects of meloxicam were observed in some animals. Meloxicam TMOS was found to be safe and effective in dogs for the control of pain and inflammation associated with osteoarthritis.
Collapse
Affiliation(s)
- E M Cozzi
- Abbott Laboratories, Abbott Park, IL, USA
| | | |
Collapse
|
8
|
Hare JE, Niemuller CA, Petrick DM. Target animal safety study of meloxicam administered via transmucosal oral spray (Promist(®) technology) for 6 months in dogs. J Vet Pharmacol Ther 2012; 36:412-6. [PMID: 23009183 DOI: 10.1111/jvp.12018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2012] [Accepted: 08/30/2012] [Indexed: 11/30/2022]
Abstract
This study evaluated the safety of meloxicam administered via transmucosal oral spray (TMOS) at 1, 2, 3 and 5 times the maximum proposed dose for 6 months in dogs. After baseline assessments, 40 Beagles (20 M, 20 F) were randomized to gender-balanced groups administered either water or meloxicam TMOS at 1, 2, 3 and 5 times the maximum proposed dose once daily for 26 weeks. Dogs were subjected to daily food consumption measurements and clinical and dose site observations. Periodic evaluations were made of body weight, physical examination, clinical pathology, urinalysis, buccal mucosal bleeding time (BMBT) and gastroduodenal endoscopy. At study completion, all dogs were subjected to gross necropsy. Histopathology was performed on tissues from dogs in groups 0X and 5X and from selected tissues in other dose groups. Clinical signs of previously reported NSAID-associated gastrointestinal upset were noted with higher frequency in meloxicam-dosed animals than in controls. Despite the presence of statistically significant effects on some clinicopathological variables, no toxicologically relevant dose-associated effects were determined on these or on food consumption, dose site observations, body weight, physical examination, urinalysis, BMBT, endoscopic examination or gross and histopathological examination of necropsy tissues.
Collapse
Affiliation(s)
- J E Hare
- Kingfisher International, Inc, Stouffville, ON, Canada.
| | | | | |
Collapse
|